Effective October 1, 2026
Members of the Global Healthcare Accreditation (GHA) Scientific Advisory Council on Longevity must disclose any financial or professional interest that could influence their advice on the Healthy Longevity Medicine Standard. Members with a conflict do not vote on the affected decisions. GHA publishes a summary of each member’s disclosures on this page.
The Healthy Longevity Medicine Standard is used by clinics, employers, insurers and patients to decide which longevity care providers to trust. That trust depends on the standard being written independently of the companies and products it evaluates. This policy explains how GHA identifies and manages conflicts of interest so that the Council’s advice reflects the evidence and nothing else.
This policy applies to every member of the Scientific Advisory Council on Longevity. It also applies to invited experts who give the Council evidence or advice on a specific topic.
Members disclose any interest held in the past 36 months by themselves, their spouse or partner, or their dependent children. Interests include:
Having expertise, publications or a public scientific view on a topic is not a conflict of interest. A financial interest in the outcome is.
GHA reviews every disclosure and assigns one of three outcomes for each review item:
For example, a member who holds a patent on, or receives income from, a biological age test may share scientific evidence on biological age testing. That member does not vote on whether such tests may be used clinically, or on any requirement that names a specific test.
Members may describe their role on the Council. Members may not use their membership, or GHA’s name, to market or endorse any product, test, clinic or service. Members may not accept payment from an accredited or applicant organization in connection with that organization’s accreditation.
A member who fails to disclose an interest, or takes part in a decision despite a conflict, may be asked to step down. GHA will review any decision affected by an undisclosed conflict and may reopen it.
No. Many leading scientists in longevity medicine have ties to companies. The policy requires these interests to be disclosed and managed, so that the Council can draw on the best expertise while keeping its decisions independent.
Yes, as a source of evidence. They do not vote on decisions that affect the test’s used
A summary for each member appears on this page once members are confirmed.